Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Christina A Meyers, Paul D Brown

Abstract

The inclusion of neurocognitive end points in clinical trials of patients with CNS tumors is increasing. Neurocognitive end points are used to understand what cognitive problems exist before treatment to establish a baseline by which the effect of treatment is judged, and to determine whether different treatment regimens improve neurocognitive function due to better tumor control, slow expected neurocognitive deterioration due to the tumor, or have more or less short- and long-term neurotoxicity. However, the use of neurocognitive end points in clinical trials for patients with CNS tumors is in its infancy, so that long-term outcomes are difficult to predict and the ability to determine the effects of different agents and treatment approaches is scant. Including this aspect of patient evaluation in addition to survival and time to tumor progression will yield better risk-versus-benefit assessments as well as provide a basis for improving interventions.

References

Dec 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A O'ShaughnessyR Temple
Jul 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C A MeyersV A Levin
Feb 2, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C A MeyersV A Levin
Aug 6, 2002·Nature Medicine·Michelle L MonjeTheo D Palmer
Aug 13, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christina A Meyers, Jeffrey S Wefel
Jan 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C KollmannsbergerC Bokemeyer
Jan 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christina A MeyersMarkus F Renschler
Jan 28, 2004·Pediatric Rehabilitation·Raymond K Mulhern, Robert W Butler
Feb 26, 2004·Lancet Neurology·Martin J B Taphoorn, Martin Klein
Mar 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W RoaP Forsyth
Apr 20, 2004·International Journal of Radiation Oncology, Biology, Physics·Paul D BrownUNKNOWN Mayo Clinic
Mar 11, 2005·The New England Journal of Medicine·Stefan RutkowskiJoachim Kuehl

❮ Previous
Next ❯

Citations

Dec 14, 2006·Current Oncology Reports·Terri S Armstrong, Mark R Gilbert
Sep 6, 2007·Cell and Tissue Research·Marta Andres-MachJohn R Fike
Mar 13, 2008·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Robert Anton OlsonMichael McKenzie
Oct 20, 2010·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Robert OlsonMichael McKenzie
Jul 5, 2011·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Elena LampertiAndrea Salmaggi
Oct 14, 2011·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·A SilvaniA Salmaggi
Apr 29, 2010·Current Neurology and Neuroscience Reports·Denise D Correa
Apr 29, 2010·Current Oncology Reports·Marc C Chamberlain
Sep 22, 2012·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Yohei MineharuMaria G Castro
Sep 10, 2013·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·G TrucG Créhange
Jan 6, 2011·Journal of the International Neuropsychological Society : JINS·Karin GehringMargriet M Sitskoorn
Apr 1, 2010·Nature Reviews. Clinical Oncology·Nicholas F Marko, Robert J Weil
Nov 11, 2009·Proceedings of the National Academy of Sciences of the United States of America·Munjal M AcharyaCharles L Limoli
Jul 1, 2010·AJOB Neuroscience·Lisa Anderson-ShawJ Lee Villano
Feb 8, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D D CorreaD Schiff
Feb 12, 2011·Neuro-oncology·David A ReardonPatrick Y Wen
May 12, 2011·Neuro-oncology·Jeffrey S WefelHenry S Friedman
Nov 1, 2012·Neuro-oncology·Dana Greene-Schloesser, Mike E Robbins
Nov 1, 2012·Neuro-oncology·Rakesh Jalali, Debnarayan Dutta
Sep 29, 2011·Cognitive and Behavioral Neurology : Official Journal of the Society for Behavioral and Cognitive Neurology·Michelle BraunTeresa Deer
Feb 19, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yue CaoTheodore S Lawrence
Aug 30, 2008·Neuro-oncology·Christina A MeyersMichael D Prados
Jun 5, 2012·PloS One·Peter H WuDavid R Grosshans
Nov 2, 2011·Journal of Visualized Experiments : JoVE·Lori-Ann ChristieCharles L Limoli
May 30, 2013·Journal of Neurology, Neurosurgery, and Psychiatry·Susan G R McDuffClark C Chen
Jun 17, 2014·Seminars in Radiation Oncology·Christina TsienThomas Chenevert
Dec 3, 2014·Brain and Cognition·Viviane Luherne-du BoullayLaurence Chaby
Aug 15, 2014·Journal of Neuro-oncology·Katherine B PetersLee W Jones
Sep 18, 2014·Current Treatment Options in Oncology·Albert AttiaMichael Chan
May 5, 2010·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Robert OlsonMichael McKenzie
Feb 8, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dana Greene-SchloesserMike E Robbins
Oct 25, 2013·Expert Review of Anticancer Therapy·Giovanni CitterioMichele Reni

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.